/TNFA
TNFA Stock - TNF Pharmaceuticals, Inc.
Healthcare|BiotechnologyNASDAQ
$5.20+48.15%
+$1.69 (+48.15%) • Sep 24
40
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.0
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.29
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $5.72
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for TNFA
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$5.15 – $5.25
TARGET (TP)$5.98
STOP LOSS$4.78
RISK/REWARD1:1.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta2.28
52W High$195.00
52W Low$3.24
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | $-29,452 |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-10,168,790 | $-17,123,052 | $-15,282,760 | $-28,201,247 | $-12,285,703 |
| Net Income | $-23,359,334 | $-3,999,950 | $-15,197,336 | $-29,889,045 | $-17,580,609 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-1115.00 | $-533.00 | $-1174.00 | $-2561.00 | $-14956.00 |
Company Overview
TNF Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company. It focuses on developing two novel therapeutic platforms that treat the causes of disease rather than addressing the symptoms. Its MYMD-1 is a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. The MYMD-1 is being developed to delay aging, increase longevity, and treat autoimmune diseases. The company's second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction, and epilepsy. The Supera-CBD is a novel synthetic derivative of cannabidiol (CBD) and is being developed to address and improve the growing CBD market, which includes FDA approved drugs and CBD products not regulated as drugs. TNF Pharmaceuticals, Inc. was formerly known as MyMD Pharmaceuticals, Inc. and changed its name to TNF Pharmaceuticals, Inc. in July 2024. The company was founded in 2014 and is headquartered in Baltimore, Maryland.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
TNFABeat Rate
0%
Last 0 quarters
Avg Surprise
+0%
EPS vs Estimate
Beats / Misses
0/0
Last 12 quarters
Latest EPS
$-18.00
Q3 2025
EPS Surprise History
Q3 23
No data
Q1 24
No data
Q2 24
No data
Q3 24
No data
Q4 24
No data
Q2 25
No data
Q2 25
No data
Q3 25
No data
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q3 2025 | Aug 19, 2025 | — | $-18.00 | — | — |
Q2 2025 | May 15, 2025 | — | $-0.36 | — | — |
Q2 2025 | Apr 11, 2025 | — | $-0.66 | — | — |
Q4 2024 | Nov 14, 2024 | — | $-1.11 | — | — |
Q3 2024 | Aug 19, 2024 | — | $-1.81 | — | — |
Q2 2024 | May 15, 2024 | — | $-5.14 | — | — |
Q1 2024 | Mar 31, 2024 | — | $-4.58 | — | — |
Q3 2023 | Sep 30, 2023 | — | $2.70 | — | — |
Q2 2023 | Jun 30, 2023 | — | $-3.10 | — | — |
Q1 2023 | Mar 31, 2023 | — | $-1.14 | — | — |
Q4 2022 | Dec 31, 2022 | — | $-2.85 | — | — |
Q3 2022 | Sep 29, 2022 | — | $-2.84 | — | — |
Q2 2022 | Jun 29, 2022 | — | $-2.85 | — | — |
Q1 2022 | Mar 30, 2022 | — | $-3.24 | — | — |
Q4 2021 | Dec 30, 2021 | — | $-2.58 | — | — |
Q3 2021 | Sep 29, 2021 | — | $-4.36 | — | — |
Q2 2021 | Jun 30, 2021 | — | $-15.12 | — | — |
Q1 2021 | Mar 31, 2021 | — | $-2.50 | — | — |
Q4 2020 | Dec 31, 2020 | — | $-37.39 | — | — |
Q3 2020 | Sep 30, 2020 | — | $-2.52 | — | — |
Latest News
TNF Pharmaceuticals shares are trading higher. The company announced it changed its name to Q/C Technologies.
➖ NeutralBenzinga•Sep 24, 2025, 03:34 PM
TNF Pharmaceuticals Rebrands As Q/C Technologies, Shifts To Quantum-Class Computing With New Ticker Symbol 'QCLS', Effective September 25, 2025
📈 PositiveBenzinga•Sep 24, 2025, 01:16 PM
TNF Pharma Regains Nasdaq Compliance
📈 PositiveBenzinga•Sep 17, 2025, 01:25 PM
PharmaCyte Biotech Invests Additional $3M In TNF Pharmaceuticals To Support LightSolver Partnership
📈 PositiveBenzinga•Sep 2, 2025, 01:22 PM•Also:
TNF Pharmaceuticals Licenses LightSolver's Laser-Based Computing Tech For Blockchain; Plans Name Change
📈 PositiveBenzinga•Sep 2, 2025, 01:16 PM
Trading Halt: Halt status updated at 8:55:00 AM ET: Quotation Resumption: News and Resumption Times
➖ NeutralBenzinga•Sep 2, 2025, 12:55 PM
TNF Pharmaceuticals shares are trading lower after the company announced a 1-for-100 reverse stock split.
📉 NegativeBenzinga•Aug 28, 2025, 04:07 PM
TNF Pharmaceuticals to execute reverse stock split
📉 NegativeSeeking Alpha•Aug 28, 2025, 01:28 PM
TNF Pharma Announces 1-For-100 Reverse Stock Split Effective Sept. 2; Operational Updates Expected Post-Split
📉 NegativeBenzinga•Aug 28, 2025, 01:20 PM
TNF Pharmaceuticals Q2 EPS $(0.18) Up From $(4.54) YoY
📈 PositiveBenzinga•Aug 19, 2025, 09:54 PM
TNF Pharmaceuticals Improves Its Financial Position Over The Past 5 Months Through A Material Reduction In Liabilities, While Maintaining Total Assets Of Over $17M As Of June 30, 2025
📈 PositiveBenzinga•Aug 19, 2025, 09:22 PM
Frequently Asked Questions about TNFA
What is TNFA's current stock price?
TNF Pharmaceuticals, Inc. (TNFA) is currently trading at $5.20 per share. The stock has moved +48.15% today.
What is the analyst price target for TNFA?
No analyst price targets are currently available for this stock.
What sector is TNF Pharmaceuticals, Inc. in?
TNF Pharmaceuticals, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is TNFA's market cap?
TNF Pharmaceuticals, Inc. has a market capitalization of $0.01 billion, making it a small-cap company.
Does TNFA pay dividends?
No, TNF Pharmaceuticals, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorAPGN
Apexigen, Inc.
$0.39
Mkt Cap: $0.0B
BIOR
Biora Therapeutics, Inc.
$0.22
Mkt Cap: $0.0B
CHRO
Channel Therapeutics Corporation
$1.35
Mkt Cap: $0.0B
CRVO
CervoMed Inc.
$7.60
Mkt Cap: $0.1B
CSCI
COSCIENS Biopharma Inc.
$2.11
Mkt Cap: $0.0B
CYCC
Cyclacel Pharmaceuticals, Inc.
$6.37
Mkt Cap: $0.0B
IMVIF
IMV Inc.
$0.00
Mkt Cap: $0.0B
OMGA
Omega Therapeutics, Inc.
$0.14
Mkt Cap: $0.0B
TSBX
Turnstone Biologics Corp.
$0.35
Mkt Cap: $0.0B
TVRD
Tvardi Therapeutics, Inc.
$3.98
Mkt Cap: $0.0B
Explore stocks similar to TNFA for comparison